Bio Medica Laboratories Limited
1. Overview
Bio Medica Laboratories Limited (BMLL) is an Indore, Madhya Pradesh-based pharmaceutical company incorporated on August 14, 2015, engaged exclusively in the contract manufacturing of Pharmaceutical Parenteral Formulations — generic injectable drugs in the form of Liquid Injections and Dry Powder Injections for both human and veterinary applications.
BMLL operates on a pure B2B contract manufacturing model, producing formulations for third-party pharmaceutical companies who market the products under their own brand names. The company holds GMP and GLP certifications from the Food & Drugs Administration, Madhya Pradesh, affirming compliance with established manufacturing standards. Its manufacturing and registered office are co-located at Indore's Industrial Estate (Sector-E, Sanwer Road), making it a single-site operation.
Over the three years from FY23 to FY25, BMLL has grown from revenue of ₹16.23 crore in FY23 to ₹38.20 crore in FY25 — a CAGR of approximately 53%. For the eight-month period ended November 30, 2025, the company reported consolidated revenue of ₹28.55 crore. Profitability has accelerated sharply, with PAT rising from ₹0.33 crore (FY23) to ₹9.79 crore (FY25), reflecting a rapid improvement in operating leverage and client volumes.
The company is promoted by Mr. Pradeep Mehta (Managing Director, 19+ years in pharma) and Mr. Mukesh Mehta (Whole-Time Director, 18+ years), who collectively hold approximately 96.84% of pre-IPO equity and each offer 1,88,500 shares under the OFS component.
2. Business Model and Revenue Streams
Revenue Breakdown
BMLL's revenue is derived from two primary streams:
| Revenue Source | Description |
|---|---|
| Sale of Manufactured Goods | Revenue from production and sale of Liquid and Dry Powder Injectables manufactured at its Indore facility |
| Sale of Trading Goods | Revenue from trading of raw materials — base chemicals used in the production process, tablets, and packing materials |
The company does not operate direct-to-consumer channels. All products are manufactured to client specifications and dispatched with the client's name as "Technical Collaborator" or "marketed by," with Bio Medica's name as the manufacturer of record. This keeps the revenue model asset-light from a marketing and distribution perspective while creating dependency on a concentrated client base.
Client Concentration and Pricing
As a contract manufacturer, revenue is driven entirely by client order volumes — there are no long-term take-or-pay contracts mentioned in the RHP
The company explicitly acknowledges in its risk factors that it is dependent on a limited number of clients for a significant portion of revenues, and loss of any key client could materially impact financials
Pricing is on a cost-plus or negotiated basis per formulation type; the company competes on quality compliance, lead time, and capacity availability
3. Products and Service Portfolio
3.1 Liquid Injectables
BMLL manufactures 58 products under its liquid injectable category, available in ampoules and vials in both single-dose and multi-dose formats for human and veterinary applications.
Top 5 Revenue-Generating Liquid Injectables:
| Product | Therapeutic Category |
|---|---|
| Amikacin Sulphate Injection (100ml) | Antibiotics — bacterial infection treatment |
| Vitamin B12, D3 & Calcium Gluconolactobionate Injection | Nutritional supplement — bone/nerve health |
| Amikacin Sulphate Injection (2ml) | Antibiotics |
| Buprenorphine Injection | Analgesics — severe pain management |
| Amikacin Sulphate Injection (30ml) | Antibiotics |
Amikacin-based formulations are clearly the dominant revenue contributors within the liquid injectable segment, indicating a degree of product concentration.
3.2 Dry Powder Injectables
The company manufactures dry powder injectables available in vials for both human and veterinary markets. These require specialised manufacturing infrastructure (aseptic/sterile suites) due to their sensitivity to moisture and temperature.
3.3 Manufacturing Infrastructure
- Single manufacturing site: Indore Industrial Estate — houses registered office, manufacturing plant, QC laboratory, and warehouse
- In-house laboratory: Equipped with HPLC, GC, UV-Vis spectrophotometer, polarimeter, and other advanced instruments for comprehensive physical testing, process controls, and stability studies
- Capacity expansion: The company is using ₹29.28 crore (~₹28.50 crore from IPO proceeds) to set up a new manufacturing facility at the existing premises, with civil construction beginning June 2026 and commercial operations targeted by July 2027
4. Key Business Strengths
- Certified quality infrastructure: GMP and GLP certifications from Madhya Pradesh FDA demonstrate manufacturing compliance and are prerequisites for client acquisition in the B2B pharma space
- Broad product breadth: A portfolio of 58 liquid injectable formulations across antibiotic, analgesic, and nutritional categories gives the company flexibility to service diverse client requirements
- Experienced founding promoters: Mr. Pradeep Mehta and Mr. Mukesh Mehta, both founders, have managed the company since incorporation with a combined 37+ years of pharmaceutical sector experience
5. Future Growth Strategy
- Capacity doubling: The primary use of IPO proceeds (₹28.50 crore) is to expand manufacturing capacity at the Indore site — civil works (June 2026 – May 2027) and plant & machinery commissioning (November 2026 – April 2027), with commercial operations from July 2027 — enabling the company to win larger or additional client contracts
- Debt deleveraging: ₹6.50 crore from IPO proceeds will repay high-cost borrowings, reducing total interest burden (finance costs were ₹1.17 Cr in 8MFY26 and ₹1.19 Cr in FY25) and improving net profit margins which were 25.6% in FY25
- Veterinary injectables as growth adjacency: The explicit product portfolio coverage of veterinary applications alongside human pharma suggests a diversification strategy to tap the growing animal health injectable segment in India
- GCP funding for general corporate purposes and marketing capability build-out to acquire additional contract manufacturing clients — particularly important given the single-client-concentration risk
- Regulatory compliance investment: As the company scales, maintaining ongoing GMP certification and potential upgrades (WHO-GMP, EU-GMP for export-eligible manufacturing) will be strategic levers to attract MNC contract manufacturing client
